Welcome to AiCuris: The Powerhouse for Anti-Infectives    


“Committed to making the difference”

AiCuris is a pharmaceutical company focused on the discovery, research and development of novel, resistance-breaking antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.

Founded in 2006 as a spin-out from Bayer's virology and bacteriology research department, AiCuris is now an established “powerhouse for anti-infectives” and is one of the few biotech companies world-wide to have successfully brought a drug to market, and therefore to patients (Prevymis® 2017/18).

Today AiCuris has an innovative pipeline of anti-infective agents and a team of internationally recognized scientists in Research and Development. By focusing on therapeutic areas with high medical need, the company is positioned for growth and success.

Cooperation with Lysando

AiCuris and Lysando join forces in the fight against antimicrobial resistance

Lysando AG and AiCuris today annouced the signing of a long-term cooperation for the development and optimization of Artilysin®-based drug candidates for various anti-bacterial indications.

Read more ...

Investment in Wuppertal

AiCuris plans its further growth in Wuppertal and intends investing millions at the site

Investments amounting to several million euros are planned over the next few years for the modernisation and expansion of the premises and laboratories.

Read more ...

Job Opportunities

Join AiCuris and its quest for novel Anti-Infectives

We offer an exciting and challenging working enviroment in an innovative company with a world-class  R&D Portfolio.

Read more ...